DCIR4 Activators
DCIR4 Activators, encompassing a range of chemical compounds, play a pivotal role in modulating the functional activity of DCIR4 through various signaling pathways. These activators, though diverse in their mechanisms, predominantly influence the intracellular levels of cAMP or cGMP, leading to the activation of protein kinase A (PKA), a crucial mediator in DCIR4-associated signaling cascades. For instance, Forskolin, by elevating cAMP, indirectly enhances DCIR4's activity by promoting PKA activation, which phosphorylates specific substrates in pathways where DCIR4 is active. Similarly, IBMX, as a non-selective inhibitor of phosphodiesterases, increases both cAMP and cGMP levels, thereby indirectly influencing DCIR4's activity through PKA. This theme of indirect activation via modulation of cAMP levels is also evident in compounds like Rolipram, Cilostamide, and Milrinone, which, by inhibiting specific phosphodiesterases, lead to enhanced DCIR4 activity via the cAMP-PKA signaling axis.
Moreover, other activators such as Sildenafil, Vinpocetine, and Isoproterenol demonstrate the intricate cross-talk between cAMP and cGMP pathways and their collective impact on DCIR4 activation. Sildenafil, primarily targeting phosphodiesterase 5, indirectly affects DCIR4 by altering cGMP levels, which can influence cAMP pathways, ultimately leading to PKA activation and enhanced DCIR4 activity. The influence of adrenergic agonists like Isoproterenol and hormones such as Glucagon and Epinephrine further underscores the complexity of DCIR4 regulation. These compounds increase cAMP levels via adenylate cyclase activation, subsequently enhancing DCIR4 activity through PKA-mediated pathways. Additionally, neurotransmitters like Dopamine and Histamine, through their receptor-mediated actions, contribute to the dynamic regulation of DCIR4 by modulating adenylate cyclase activity and, in turn, influencing cAMP levels and PKA activation. Collectively, these DCIR4 Activators, through their targeted effects on key signaling molecules and pathways, facilitate the nuanced modulation of DCIR4's functional activity, underscoring the intricate network of biochemical interactions that govern its role in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly enhances the activity of DCIR4 by elevating intracellular cAMP levels. This increase in cAMP activates protein kinase A (PKA), which then can phosphorylate specific substrates involved in the signaling pathways where DCIR4 is active, leading to its functional activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, a non-selective inhibitor of phosphodiesterases, increases intracellular cAMP and cGMP levels. This elevation indirectly enhances DCIR4 activity by promoting PKA activation, which is involved in pathways where DCIR4 plays a role. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a selective inhibitor of phosphodiesterase 4, elevates cAMP levels by preventing its breakdown. Increased cAMP activates PKA, which then modulates the signaling cascades involving DCIR4, leading to its enhanced functional activity. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a selective inhibitor of phosphodiesterase 3, leads to an increase in cAMP levels. This rise in cAMP indirectly enhances DCIR4's activity through the activation of PKA, a key player in DCIR4-related signaling pathways. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a phosphodiesterase 3 inhibitor, increases intracellular cAMP levels. Elevated cAMP activates PKA, which influences various signaling pathways where DCIR4 is functionally active, thus enhancing DCIR4's activity. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine, a phosphodiesterase 1 inhibitor, raises cAMP and cGMP levels, indirectly enhancing DCIR4 activity. This is achieved by activating PKA, which then modulates signaling pathways in which DCIR4 is involved. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a non-selective beta-adrenergic agonist, increases cAMP levels by activating adenylate cyclase. The resultant elevation in cAMP enhances DCIR4 activity by activating PKA, a key component in DCIR4-mediated signaling pathways. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, acting as a stimulant of adenylate cyclase via beta-adrenergic receptors, increases cAMP levels. This elevation indirectly enhances DCIR4 activity by activating PKA, which modulates DCIR4-related signaling pathways. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can indirectly influence DCIR4 activity through its action on dopamine receptors that interact with adenylate cyclase, leading to increased cAMP levels and subsequent PKA activation, a critical modulator in DCIR4's signaling pathways. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine, interacting with its receptors, can lead to an increase in intracellular cAMP levels, indirectly enhancing DCIR4 activity. This is achieved through the activation of PKA, which plays a pivotal role in the signaling pathways involving DCIR4. | ||||||